Alto Neuroscience Inc. Insider Trading

ANRO

Last 12 months

Insiders sold $3.57M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jul 2024.

Net open-market

−$3.57M

0 buys · 1 sale

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 1

executives and directors

Last open-market buy

Jul 2024

Jul 10, 2024

Get an email when ANRO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 29 – 30	Nicholas Conrad Smith President and CFO	Sold10b5-1 plan 3 parts	134,886	$26.45 average	$3.57M	85%	Form 4

Sep 29 – 3010b5-1 plan
Nicholas Conrad Smith
President and CFO · sold 134,886 at avg $26.45
$3.57M
85% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ANRO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ANRO

CompareIntrinsic value

INOInovio Pharmaceuticals, Inc.

$1.62-2.41%10

SPRBSpruce Biosciences Inc.

$46.61+8.88%10

ALTAltimmune, Inc.

$2.12+3.92%10

AZTRAzitra Inc.

$0.82-7.69%19

CNTBConnect Biopharma Holdings Ltd.

$0.78+0.90%10

XLOXilio Therapeutics, Inc.

$8.71+0.35%40

LQDALiquidia Corporation

$47.38+12.27%72

BOLTBolt Biotherapeutics Inc.

$6.54-0.46%25

Held by ETFs

ANRO is in 20 US ETFs. The largest of them, with ANRO's weight in each:

Spot a number that looks wrong? Check it in ANRO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ANRO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.